MENNA, PIERANTONIO
 Distribuzione geografica
Continente #
EU - Europa 50
AS - Asia 1
Totale 51
Nazione #
IT - Italia 42
PT - Portogallo 3
DE - Germania 2
CH - Svizzera 1
PL - Polonia 1
SY - Repubblica araba siriana 1
UA - Ucraina 1
Totale 51
Città #
Rome 31
Lanciano 3
Milan 3
Basiliano 2
Frankfurt am Main 2
Macerata 2
Pontinha 2
Bogatynia 1
Bologna 1
Lisbon 1
Totale 48
Nome #
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers, file de024af2-b635-70dc-e053-6605fe0a0424 24
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, file de024af2-6847-70dc-e053-6605fe0a0424 7
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death, file d06ae3bb-9c26-4c08-8bf2-5fac644ae41a 3
Anthracycline Cardiotoxicity, file de024af2-2136-70dc-e053-6605fe0a0424 3
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin, file 3e4965d3-f48a-462c-b2db-52391c48f607 2
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker?, file 84b64077-5056-42e8-820a-c40aaa0ae365 2
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION, file a0fad69f-cbe2-45ac-b00a-22001dd32221 2
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin, file de024af2-067c-70dc-e053-6605fe0a0424 2
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite, file de024af2-18b7-70dc-e053-6605fe0a0424 2
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial, file de024af2-624a-70dc-e053-6605fe0a0424 2
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin, file de024af2-6ca8-70dc-e053-6605fe0a0424 2
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin, file de024af2-b8d4-70dc-e053-6605fe0a0424 2
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines, file de024af2-b8d8-70dc-e053-6605fe0a0424 2
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples, file ce77ec0f-f402-48b3-8d48-b41397be78b6 1
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients, file de024af2-0178-70dc-e053-6605fe0a0424 1
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab, file de024af2-07fb-70dc-e053-6605fe0a0424 1
Anthracyclines, file de024af2-107b-70dc-e053-6605fe0a0424 1
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox, file de024af2-19f1-70dc-e053-6605fe0a0424 1
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind, file de024af2-35fe-70dc-e053-6605fe0a0424 1
What is cardiotoxicity?, file de024af2-36e4-70dc-e053-6605fe0a0424 1
In ®Entresto we trust, file de024af2-5273-70dc-e053-6605fe0a0424 1
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin, file de024af2-63fb-70dc-e053-6605fe0a0424 1
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies, file de024af2-73cd-70dc-e053-6605fe0a0424 1
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues., file de024af2-7a99-70dc-e053-6605fe0a0424 1
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis, file de024af2-82dd-70dc-e053-6605fe0a0424 1
Cardio-oncology in clinical studies and real life, file de024af2-9d65-70dc-e053-6605fe0a0424 1
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study, file de024af2-a731-70dc-e053-6605fe0a0424 1
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology, file de1baa08-f29f-445f-9757-bd93702b8dc5 1
Totale 70
Categoria #
all - tutte 163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 163


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 1 1 0 0 0 0 17 0 0 1 0
2022/202324 0 0 0 0 0 0 3 0 1 8 3 9
2023/202426 0 1 1 1 1 5 8 5 1 3 0 0
Totale 70